BX Swiss TOP 30 CHF

BX Swiss TOP 30 CHF handeln
1.371,14 PKT -3,34 PKT -0,24 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN SL0CLV

ISIN DE000SL0CLV3


Analysen zu BX Swiss TOP 30 CHF-Werten

Datum Rating Analyst
30.10.12 Straumann underperform Cheuvreux SA
30.10.12 UBS underperform Cheuvreux SA
30.10.12 Geberit outperform Cheuvreux SA
30.10.12 Nestlé hold Vontobel Research
30.10.12 Straumann neutral Sarasin Research
30.10.12 Geberit neutral Sarasin Research
30.10.12 Swiss Re buy Vontobel Research
30.10.12 ABB (Asea Brown Boveri) equal-weight Morgan Stanley
30.10.12 UBS outperform RBC Capital Markets
30.10.12 Adecco SA buy Vontobel Research
30.10.12 ABB (Asea Brown Boveri) buy Vontobel Research
30.10.12 Straumann hold Vontobel Research
30.10.12 UBS buy Vontobel Research
30.10.12 Geberit hold Vontobel Research
30.10.12 UBS halten Independent Research GmbH
29.10.12 Holcim hold Deutsche Bank AG
29.10.12 Holcim hold Deutsche Bank AG
29.10.12 Nestlé kaufen Hamburger Sparkasse AG (Haspa)
29.10.12 Novartis halten Independent Research GmbH
29.10.12 UBS overweight J.P. Morgan Cazenove
29.10.12 Sonova buy Vontobel Research
29.10.12 UBS hold Société Générale Group S.A. (SG)
29.10.12 Swiss Re buy Vontobel Research
29.10.12 Schindler hold Vontobel Research
29.10.12 UBS neutral UBS AG
29.10.12 Julius Bär buy UBS AG
29.10.12 UBS hold Vontobel Research
29.10.12 UBS neutral Sarasin Research
29.10.12 ABB (Asea Brown Boveri) halten Independent Research GmbH
29.10.12 Novartis outperform Credit Suisse Group
26.10.12 ABB (Asea Brown Boveri) hold Société Générale Group S.A. (SG)
26.10.12 ABB (Asea Brown Boveri) outperform Exane-BNP Paribas SA
26.10.12 Novartis outperform Exane-BNP Paribas SA
26.10.12 Novartis buy Société Générale Group S.A. (SG)
26.10.12 Logitech outperform Exane-BNP Paribas SA
26.10.12 Logitech neutral UBS AG
26.10.12 UBS neutral Nomura
26.10.12 UBS hold Société Générale Group S.A. (SG)
26.10.12 UBS neutral Exane-BNP Paribas SA
26.10.12 UBS equal-weight Morgan Stanley